IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Obj. Deadline**: **Dec. 4, 2026 at 4:00 p.m. (ET)** **Hearing Date**: **Dec. 15, 2026 at 10:00 a.m. (ET)**

DEBTOR'S FIRST OMNIBUS OBJECTION (NON-SUBSTANTIVE) TO CERTAIN (I) CLAIMS FILED ON ACCOUNT OF EQUITY INTERESTS (II) INSUFFICIENT DOCUMENTATION CLAIMS AND (III) AMENDED AND SUPERSEDED CLAIMS

THIS OBJECTION SEEKS TO DISALLOW AND EXPUNGE AND/OR MODIFY CERTAIN FILED PROOFS OF CLAIM. CLAIMANTS RECEIVING THIS OBJECTION SHOULD REVIEW THIS OBJECTION AND THE ATTACHMENTS HERETO TO DETERMINE WHETHER THIS OBJECTION AFFECTS THEIR CLAIMS AND LOCATE THEIR NAMES AND CLAIMS ON THE EXHIBITS AND SCHEDULES ATTACHED TO THIS OBJECTION.

Sangamo Therapeutics, Inc., as debtor and debtor in possession (the "**Debtor**") in the above-captioned case, hereby files this objection (the "**Objection**") and respectfully states as follows:

RELIEF REQUESTED

1. By this Objection, the Debtor seeks entry of an order, substantially in the form attached hereto as **Exhibit A** (the "**Proposed Order**"), disallowing and expunging (i) the claims asserted on account of equity interests identified on **Schedule 1** to the Proposed Order (the "**Equity Interest Claims**"), (ii) the insufficient documentation claims identified on **Schedule 2** to the Proposed Order (the "**Insufficient Documentation Claims**"), and (iii) the amended and superseded claims identified on **Schedule 3** to the Proposed Order (the "**Amended and**

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 470 Noor Ave., Suite B #1306, South San Francisco, CA 94080.

2610989261113000000000007

Superseded Claims," and together with the Equity Interest Claims and the Insufficient Documentation Claims, the "**Disputed Claims**").

2. In support of this Objection, the Debtor submits the *Declaration of Raymond Li in Support of the Debtor's First Omnibus Objection (Non-Substantive) to Certain (I) Claims Filed on Account of Equity Interests, (II) Insufficient Documentation Claims, and (III) Amended and Superseded Claims*, attached hereto as **Exhibit B** (the "**Li Declaration**").

JURISDICTION AND VENUE

3. The United States Bankruptcy Court for the District of Delaware (this "**Court**") has jurisdiction to consider this Objection under 28 U.S.C. §§ 157 and 1334 and the *Amended Standing Order of Reference* from the United States District Court for the District of Delaware dated February 29, 2012 (Sleet, C.J.). This is a core proceeding under 28 U.S.C. § 157(b). Venue of this Chapter 11 Case (as defined below) and this Objection is proper in this District under 28 U.S.C. §§ 1408 and 1409.

4. The statutory and legal predicates for the relief requested herein are section 502 of title 11 of the United States Code (the "**Bankruptcy Code**"), rule 3007 of the Federal Rules of Bankruptcy Procedure (the "**Bankruptcy Rules**"), and rule 3007-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "**Local Rules**").

5. Pursuant to Local Rule 9013-1(f), the Debtor consents to the entry of a final order or judgment with respect to this Objection if it is determined that this Court lacks Article III jurisdiction to enter such final order or judgment absent consent of the parties.

BACKGROUND

I. General Background

6. On June 23, 2026 (the "**Petition Date**"), the Debtor commenced with the Court a voluntary case under chapter 11 of the Bankruptcy Code (this "**Chapter 11 Case**"). The Debtor

continues to operate its business and manage its properties as a debtor in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

7. On July 2, 2026, the Office of the United States Trustee for the District of Delaware (the "**U.S. Trustee**") appointed the Official Committee of Unsecured Creditors in this Chapter 11 Case (the "**Creditors' Committee**").[2] On August 5, 2026, the U.S. Trustee appointed the Official Committee of Equity Holders in this Chapter 11 Case (the "**Equity Committee**").[3] To date, no request has been made for the appointment of a trustee or examiner in this Chapter 11 Case.

8. Additional factual background and information regarding the Debtor, including its business operations, its corporate and capital structure, and the events leading to the commencement of this Chapter 11 Case, are set forth in detail in the *Declaration of Scott B. Willoughby in Support of Chapter 11 Petition and First Day Motions* [Docket No. 2].

II. The Sale Transactions

9. On July 14, 2026, the Court entered an order [Docket No. 122] (the "**Bidding Procedures Order**"), which approved, among other things, certain procedures for the sale or sales of the Debtor's assets (the "**Bidding Procedures**"). Following a successful sale process in accordance with the Bidding Procedures, the Debtor ultimately achieved approval of the following sale transactions:

a. On August 20, 2026, the Court entered orders [Docket Nos. 356 and 358] approving the sales (the "**Equipment Sales**") of certain laboratory equipment, office furniture, and small laboratory items and supplies to certain purchasers. The Equipment Sales closed on or about August 20, 2026.

b. Also on August 20, 2026, the Court entered an order [Docket No. 362] approving, among other things, the sale (the "**Merope Sale Transaction**") of certain assets

[2] The U.S. Trustee filed two notices amending the membership of the Creditors' Committee following its appointment. *See* Docket Nos. 491 and 496.

[3] On September 16, 2026, the U.S. Trustee filed a notice amending the membership of the Equity Committee. *See* Docket No. 457.

to Merope Acquisition Sub, LLC. The Merope Sale Transaction closed on September 4, 2026 [Docket No. 436].

c. On September 2, 2026, the Court entered an order [Docket No. 426] approving, among other things, the sale (the "**PTC Sale Transaction**," and together with the Equipment Sales and the Merope Sale Transaction, the "**Sale Transactions**") of certain assets to PTC Therapeutics, Inc. The PTC Sale Transaction closed on September 17, 2026 [Docket No. 468].

10. On October 21, 2026, the Debtor filed a notice [Docket No. 530] establishing certain revised deadlines for the sale of the Debtor's Remaining Assets (as defined therein), including a bid deadline, auction date, and sale hearing for such assets.

III. The Bar Dates and the Bar Date Order

11. On June 24, 2026, the Court entered an order [Docket No. 55] appointing Kurtzman Carson Consultants, LLC dba Verita Global ("**Verita**") as the claims and noticing agent for the Chapter 11 Case. Verita is authorized and directed to, among other things, (i) perform noticing services and to receive, maintain, record, and otherwise administer the proofs of claim filed in this Chapter 11 Case (each, a "**Proof of Claim**," and collectively, the "**Proofs of Claim**"), (ii) serve as the custodian of Court records and the authorized repository for all Proofs of Claim filed in this Chapter 11 Case, and (iii) maintain an official claims register for the Debtor (the "**Claims Register**").

12. On July 21, 2026, the Debtor filed its schedules of assets and liabilities and statement of financial affairs [Docket Nos. 158 and 159] (the "**Schedules and Statement**").

13. On July 30, 2026, the Court entered the *Order (I) Establishing Bar Dates and Related Procedures for Filing Proofs of Claim (Including for Administrative Expense Claims Arising Under Section 503(b)(9) of the Bankruptcy Code), (II) Approving the Form and Manner of Notice Thereof, and (III) Granting Related Relief* [Docket No. 209] (the "**Bar Date Order**"). On the same day, the Debtor filed the *Notice of Deadlines for Filing Proofs of Claim (Including*

for Administrative Expense Claims Arising Under Section 503(b)(9) of the Bankruptcy Code) [Docket No. 210] (the "**Bar Date Notice**").

14. The Bar Date Order established, among other deadlines: (i) September 22, 2026 at 5:00 p.m. (prevailing Eastern Time) as the deadline by which all entities (other than governmental units, as defined in section 101(27) of the Bankruptcy Code) holding claims, whether secured, unsecured priority (including claims under section 503(b)(9) of the Bankruptcy Code), or unsecured nonpriority, against the Debtor that arose prior to the Petition Date must file Proofs of Claim (the "**General Bar Date**"), and (ii) December 21, 2026 at 5:00 p.m. (prevailing Eastern Time) as the deadline by which all governmental units holding claims against the Debtor, whether secured, unsecured priority, or unsecured nonpriority, that arose before the Petition Date must file Proofs of Claim (the "**Governmental Bar Date**," and together with the General Bar Date, the "**Bar Dates**").

15. In accordance with the Bar Date Order, Verita mailed the Bar Date Notice and a proof of claim form to, among others, all of the Debtor's creditors and other known parties in interest as of the Petition Date. *See* Docket Nos. 316, 435, 441, 483 and 511. Notice of the Bar Dates was also published once in the national edition of *USA Today*. *See* Docket No. 265.

16. As of the date of this Objection, approximately 450 Proofs of Claim have been filed in this Chapter 11 Case. The Debtor, with the assistance of its advisors, is actively reviewing and reconciling the Proofs of Claim and comparing them with its books and records (the "**Books and Records**") to determine the validity of such claims.

BASIS FOR RELIEF

17. Section 502(a) of the Bankruptcy Code provides that a filed proof of claim is "deemed allowed, unless a party in interest . . . objects." 11 U.S.C. § 502(a). When asserting a

proof of claim against a bankrupt estate, a claimant must allege facts that, if true, would support a finding that the debtor is legally liable to the claimant. *In re Allegheny Int'l, Inc.*, 954 F.2d 167, 173 (3d Cir. 1992); *see also In re F-Squared Investment Management, LLC*, 546 B.R. 538, 542 n.21 (Bankr. D. Del. 2016) (noting that *Allegheny* provides the standards for reviewing claims objections) (citing *In re Nortel Networks, Inc.*, 469 B.R. 478, 497 (Bankr. D. Del. 2012)). Where the claimant alleges sufficient facts to support its claim, its claim is afforded prima facie validity. *Allegheny*, 954 F.2d at 173. A party wishing to dispute a claim's validity must produce evidence sufficient to negate the claim's prima facie validity. *Id*. at 173-74. Once an objecting party produces such evidence, the burden shifts back to the claimant to prove the validity of his or her claim by a preponderance of the evidence. *Id*. at 174; *see also F-Squared*, 546 B.R. at 544 ("If an objector meets its burden of production, then the claimant must satisfy its ultimate burden of persuasion.").

a. Equity Interest Claims

18. As set forth in the Li Declaration, based upon a review and analysis of the Equity Interest Claims listed on **Schedule 1** to the Proposed Order, the Debtor has determined that each Equity Interest Claim was filed by a shareholder based on the asserted ownership of equity securities in the Debtor. The Bankruptcy Code defines an "equity security" as a:

> (A) share in a corporation, whether or not transferable or denominated "stock", or similar security;
>
> (B) interest of a limited partner in a limited partnership; or
>
> (C) warrant or right, other than a right to convert, to purchase, sell, or subscribe to a share, security, or interest of a kind specified in subparagraph (A) or (B) of this paragraph.

11 U.S.C. § 101(16). Holders of equity securities, such as shares of stock, do not have "claims" under section 101(5) of the Bankruptcy Code, but rather hold equity interests. *See In re Insilco*

Techs., Inc., 480 F.3d 212, 218 (3d Cir. 2007) ("[An equity interest] is not a claim at all[.]"); *In re Hedged-Invs. Assocs.*, 84 F.3d 1267, 1272 (10th Cir. 1996) ("Simply put, an equity interest is not a claim against the debtor[.]") (quotations omitted). The Equity Interest Claims do not assert any claims for damages, but rather assert claims based only on ownership of an equity interest.[4] Moreover, as set forth in the Bar Date Order, holders of equity interests were not required to file a Proof of Claim. *See* Bar Date Order ¶ 12(j).

19. The claims asserted by the holders of the Equity Interest Claims are not in fact claims against the Debtor. Therefore, the Debtor (i) objects to the allowance of the Equity Interest Claims set forth on **Schedule 1** to the Proposed Order and (ii) seeks entry of the Proposed Order disallowing and expunging the Equity Interest Claims.

b. Insufficient Documentation Claims

20. As set forth in the Li Declaration, based upon a review and analysis of the Insufficient Documentation Claims listed on **Schedule 2** to the Proposed Order and the Debtor's Books and Records, the Debtor has determined that each Insufficient Documentation Claim lacks any supporting documentation for the existence and/or amount of the underlying claims. The Insufficient Documentation Claims are not *prima facie* valid. Pursuant to Bankruptcy Rule 3001(c), a claimant that files a proof of claim based on a writing must file an original or duplicate of the writing with the proof of claim or otherwise explain that the writing has been lost or destroyed. Only a proof of claim filed in accordance with Bankruptcy Rule 3001 constitutes *prima facie* evidence of its validity and amount.

21. Moreover, the Li Declaration explains that the Debtor and its professionals have reviewed and made reasonable efforts to research the Insufficient Documentation Claims, each of

[4] Consistent with Local Rule 3007-1(c)(v), each of the Equity Interest Claims listed on **Schedule 1** to the Proposed Order merely asserts ownership of equity interests and does not allege damages associated therewith.

which (i) does not provide sufficient information to indicate the existence, validity or amount of a claim, (ii) does not attach any documentation or include any reference to documentation that would indicate the existence, validity or amount of a debt or claim, and (iii) does not have any basis for existence, validity or amount pursuant to the Debtor's Books and Records. Without limiting the generality of the foregoing, the Debtor and its professionals have reviewed the underlying claims and have reviewed the Books and Records for information related to the claims, including, but not limited to, a review of the Schedules and Statement, the Debtor's creditor matrix [Docket Nos. 16 and 17], and the Claims Register maintained in the ordinary course by Verita, the Debtor's claims and noticing agent. Such review provided no basis or appropriate supporting documentation on which the Debtor can determine that a valid claim exists. As such, the Debtor believes the Insufficient Documentation Claims do not provide *prima facie* evidence of the existence, validity and amount of such claims.

22. Failure to disallow the Insufficient Documentation Claims will result in the applicable claimants receiving an unwarranted recovery to the detriment of other creditors. Therefore, the Debtor (i) objects to the allowance of the Insufficient Documentation Claims set forth on **Schedule 2** to the Proposed Order and (ii) seeks entry of the Proposed Order disallowing and expunging the Insufficient Documentation Claims.[5]

c. Amended and Superseded Claims

23. As set forth in the Li Declaration, based upon a careful review and analysis of the Amended and Superseded Claims listed on **Schedule 3** to the Proposed Order, the Debtor has

[5] To the extent that any of the claimants provide additional documentation with respect to the Insufficient Documentation Claims in response to this Objection, the Debtor reserves all rights to assert that such additional documentation should not be permitted and the claim should be disallowed as the claimant failed to meet its burden in a timely manner. However, to the extent that any of the additional documentation is provided and the claim is held to constitute a timely filed proof of claim that is *prima facie* valid, the Debtor reserves all rights to further object to the proof of claim on any grounds permitted under applicable law.

determined that each Amended and Superseded Claim has been amended and superseded by a later-filed claim filed by the same claimant for the same liability. The Amended and Superseded Claims no longer represent valid claims against the Debtor's estate as they have been amended and superseded by the corresponding remaining claim listed under the column titled "Remaining Claim" on **Schedule 3** to the Proposed Order (the "**Remaining Claims**").

24. The Debtor should not be required to pay twice on the same obligation. Moreover, the elimination of the Amended and Superseded Claims will enable the Debtor to maintain a Claims Register that more accurately reflects the claims that have been asserted against the Debtor's estate. Any disallowance of the Amended and Superseded Claims will not prejudice any claimants or their substantive rights against the Debtor because each Remaining Claim will remain on the Claims Register, subject to the ongoing rights of the Debtor to object to the Remaining Claims on these or any other applicable grounds, including other grounds set forth in any subsequent omnibus objections.

25. Therefore, the Debtor (i) objects to the Amended and Superseded Claims listed on **Schedule 3** to the Proposed Order and (ii) requests that such Amended and Superseded Claims listed under the column heading "Amended Claim to be Disallowed" be disallowed in their entirety.

RESPONSES TO THIS OBJECTION

26. To contest the determinations made as to the Disputed Claims included in this Objection, a claimant must file with the Office of the Clerk of the Court, 824 North Market Street, 3rd Floor, Wilmington, Delaware 19801, a written response to this Objection (a "**Response**") no later than **December 4, 2026 at 4:00 p.m. (prevailing Eastern Time)** (the "**Response Deadline**") and serve the Response upon counsel to the Debtor: (i) Cooley LLP (a) 55 Hudson Yards, New

York, NY 10001 (Attn: Cullen Dresher Speckhart and Lauren A. Reichardt) and (b) 3 Embarcadero Center, 20th Floor, San Francisco, California 94111 (Attn: Robert L. Eisenbach III); and (ii) Richards, Layton & Finger, P.A., One Rodney Square, 920 North King Street, Wilmington, Delaware 19801 (Attn: Daniel J. DeFranceschi, Amanda R. Steele, and Brendan J. Schlauch).

27. Each Response to this Objection must, at a minimum, contain the following information:

a. a caption setting forth the name of the Court, the name of the Debtor, the case number, and the title of the Objection to which the Response is directed;

b. the name of the claimant, the claim number, and a description of the basis for the amount of the claim;

c. the specific factual basis and supporting legal argument upon which the party will rely in opposing this Objection;

d. all documentation and other evidence in support of the claim not previously filed with the Court or Verita, upon which the claimant will rely in opposing this Objection; and

e. the name, address, telephone number, fax number and/or email address of the person(s) (which may be the claimant or the claimant's legal representative) with whom counsel for the Debtor should communicate with respect to the claim subject to the Objection or the Response and who possesses authority to reconcile, settle, or otherwise resolve the objection to the claim on behalf of the claimant.

28. If a claimant fails to timely file and serve a Response by the Response Deadline, the Debtor may present to the Court an appropriate order disallowing and expunging the Disputed Claims and sustaining this Objection without further notice to the claimant or a hearing.

29. The Debtor may file and serve a reply to any Response in accordance with the Local Rules. The Debtor reserves the right to seek an adjournment of the hearing on any Response to this Objection, which adjournment will be noted on the notice of agenda for the hearing.

SEPARATE CONTESTED MATTERS

30. To the extent a Response is filed regarding any claim listed in this Objection and the Debtor is unable to resolve the Response, the objection by the Debtor to such claim shall constitute a separate contested matter as contemplated by Bankruptcy Rule 9014. Any order entered by the Court regarding an objection asserted in this Objection shall be deemed a separate order with respect to each claim subject hereto.

RESERVATION OF RIGHTS

31. The Debtor reserves the right to amend, modify, and/or supplement this Objection, and to object further to each of the Disputed Claims on any and all additional factual and legal grounds. Nothing in this Objection and/or the exhibits hereto shall be construed as an admission of the amount, priority, and/or status of any claim.

COMPLIANCE WITH LOCAL RULE 3007-1

32. To the best of the Debtor's knowledge and belief, this Objection complies with Local Rule 3007-1. To the extent this Objection does not comply in all respects with the requirements of Local Rule 3007-1, the undersigned believes such deviations are not material and respectfully requests that any such requirement be waived.

NOTICE

33. Notice of this Objection will be given to (i) the U.S. Trustee; (ii) counsel to the Creditors' Committee; (iii) counsel to the Equity Committee; (iv) the Internal Revenue Service; (v) the Securities and Exchange Commission; (vi) the United States Attorney's Office for the District of Delaware and all other states in which the Debtor operates; (vii) the claimants whose claims are subject to this Objection; and (viii) any party that has requested notice pursuant to Bankruptcy Rule 2002. The Debtor believes that no further notice is required.

34. The Debtor submits that under the circumstances no other or further notice is necessary.

NO PRIOR REQUEST

35. No prior request for the relief sought herein has been made to this Court or any other court in connection with this Chapter 11 Case.

[*Remainder of page intentionally left blank*]

WHEREFORE, the Debtor respectfully requests that the Court enter the Proposed Order, granting the relief requested in the Objection and such other and further relief as may be just and proper.

Dated: November 13, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ James F. McCauley

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
James F. McCauley (No. 6991)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
mccauley@rlf.com

-and-

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com

-and-

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Obj. Deadline**: **Dec. 4, 2026 at 4:00 p.m. (ET)** **Hearing Date**: **Dec. 15, 2026 at 10:00 a.m. (ET)**

NOTICE OF OMNIBUS OBJECTION AND HEARING

PLEASE TAKE NOTICE that, on November 13, 2026, the above-captioned debtor and debtor-in-possession (collectively, the "**Debtor**") filed the *Debtor's First Omnibus Objection (Non-Substantive) to Certain (I) Claims Filed on Account of Equity Interests (II) Insufficient Documentation Claims and (III) Amended and Superseded Claims* (the "**Objection**") with the United States Bankruptcy Court for the District of Delaware (the "Court"). **Your claim(s) may be disallowed and expunged as a result of the Objection. Therefore, you should read the attached Objection carefully.**

PLEASE TAKE FURTHER NOTICE THAT YOUR RIGHTS MAY BE AFFECTED BY THE OBJECTION AND BY ANY FURTHER CLAIM OBJECTION THAT MAY BE FILED BY THE DEBTOR OR OTHERWISE. THE RELIEF SOUGHT HEREIN IS WITHOUT PREJUDICE TO THE DEBTOR'S RIGHTS TO PURSUE FURTHER OBJECTIONS AGAINST YOUR CLAIM(S) SUBJECT TO THE OBJECTION IN ACCORDANCE WITH APPLICABLE LAW AND APPLICABLE ORDERS OF THE BANKRUPTCY COURT.

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 470 Noor Ave., Suite B #1306, South San Francisco, CA 94080.

PLEASE TAKE FURTHER NOTICE that if the holder of a claim that is the subject of the Objection wishes to respond to the Objection, the holder must file a written response (each, a "Response") by **December 4, 2026 at 4:00 p.m. (ET)** and serve the Response upon counsel to (i) counsel to the Debtor, (a) Cooley LLP, Cullen Drescher Speckhart (cspeckhart@cooley.com), Lauren A. Reichardt (lreichardt@cooley.com), Robert Eisenbach, III (reisenbach@cooley.com), and Miriam Peguero Medrano (mpegueromedrano@cooley.com), and and (b) Richards, Layton & Finger, P.A., Daniel J. DeFranceschi (defranceschi@rlf.com), Amanda R. Steele (steele@rlf.com), and Brendan J. Schlauch (schlauch@rlf.com); (ii) counsel to the Official Committee of Unsecured Creditors, McDermott Will & Schulte LLP, (a) 1000 N. West Street, Suite 1400, Wilmington, Delaware 19801, Attn: David R. Hurst (dhurst@mcdermottlaw.com) and Andrew A. Mark (amark@mcdermottlaw.com) and (b) One Vanderbilt Avenue, New York, New York 10017-3852, Attn: Darren Azman (dazman@mcdermottlaw.com), Kristin K. Going (kgoing@mcdermottlaw.com) and Lindsay Barca (lbarca@mcdermottlaw.com); (iii) counsel to the Official Committee of Equity Holders (a) Orrick, Herrington & Sutcliffe LLP, 51 West 52nd St., New York, New York 10019, Attn: Nicholas Poli (npoli@orrick.com) and Mark Franke (mfranke@orrick.com), and (b) Morris James, LLP, 3205 Avenue North Blvd., Suite 100, Wilmington, Delaware 19803, Attn: Eric Monzo (emonzo@morrisjames.com) and Jason Levin (jlevin@morrisjames.com), and (iv) the U.S. Trustee, Attn: Linda J. Casey (linda.casey@usdoj.gov)).

PLEASE TAKE FURTHER NOTICE that Responses to the Objection must contain, at minimum, the following: (a) a caption setting forth the name of the Court, the name of the Debtor, the case number, and the title of the Objection to which the Response is directed; (b) the name of the claimant, the claim number, and a description of the basis for the amount of the claim; (c) the

specific factual basis and supporting legal argument upon which the party will rely in opposing the Objection; (d) all documentation and other evidence in support of the claim, not previously filed with the Court or Epiq, upon which the claimant will rely in opposing the Objection; and (e) the name, address, telephone number, fax number and/or email address of the person(s) (which may be the claimant or the claimant's legal representative) with whom counsel for the Debtor should communicate with respect to the Claim subject to the Objection or the Response and who possesses authority to reconcile, settle, or otherwise resolve the objection to the Claim on behalf of the claimant.

PLEASE TAKE FURTHER NOTICE that if no response to the Objection is timely filed and received in accordance with the above procedures, an order may be entered sustaining the Objection without further notice or a hearing. If a response is properly filed, served and received in accordance with the above procedures and such response is not resolved, a hearing to consider such response and the Objection will be held before The Honorable Craig T. Goldblatt, United States Bankruptcy Judge for the District of Delaware, at the Court, 824 North Market Street, 5th Floor, Courtroom 5, Wilmington, Delaware 19801 on **December 15, 2026 at 10:00 a.m. (ET).** Only a response made in writing and timely filed and received will be considered by the Court at the Hearing.

IF YOU FAIL TO RESPOND IN ACCORDANCE WITH THIS NOTICE, THE BANKRUPTCY COURT MAY SUSTAIN THE OBJECTION WITHOUT FURTHER NOTICE OR HEARING.

[*Remainder of page intentionally left blank*]

Dated: November 13, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ James F. McCauley

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
James F. McCauley (No. 6991)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
mccauley@rlf.com

-and-

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com

-and-

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession

EXHIBIT A

Proposed Order

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	

ORDER GRANTING THE DEBTOR'S FIRST OMNIBUS OBJECTION (NON-SUBSTANTIVE) TO CERTAIN (I) CLAIMS FILED ON ACCOUNT OF EQUITY INTERESTS, (II) INSUFFICIENT DOCUMENTATION CLAIMS AND (III) AMENDED AND SUPERSEDED CLAIMS

Upon the omnibus objection (the "**Objection**")[2] of the above-captioned debtor and debtor-in-possession (the "**Debtor**") for entry of an order (this "**Order**"), pursuant to section 502 of the Bankruptcy Code, Bankruptcy Rule 3007, and Local Rule 3007-1, disallowing and expunging, (i) the Equity Interest Claims identified on **Schedule 1** hereto, (ii) the Insufficient Documentation Claims identified on **Schedule 2** hereto, and (iii) the Amended and Superseded Claims identified on **Schedule 3** hereto, all as more fully set forth in the Objection; and it appearing that the Court has jurisdiction to consider the Objection pursuant to 28 U.S.C. §§ 1334 and 157, and the *Amended Standing Order of Reference* from the United States District Court for the District of Delaware dated February 29, 2012; and it appearing that the Objection is a core matter pursuant to 28 U.S.C. § 157(b)(2) and that the Court may enter a final order consistent with Article III of the United States Constitution; and it appearing that venue of this Chapter 11 Case and of the Objection is proper pursuant to 28 U.S.C. §§ 1408 and 1409; and it appearing that due and adequate notice of

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 470 Noor Ave., Suite B #1306, South San Francisco, CA 94080.

[2] Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Objection.

the Objection has been given under the circumstances, and that no other or further notice need be given; and after due deliberation, and good and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT:

1. The Objection is GRANTED as set forth herein.

2. Any Response to the Objection not otherwise withdrawn, resolved, or adjourned is hereby overruled on the merits.

3. Each Equity Interest Claim identified on **Schedule 1** hereto is disallowed and expunged in its entirety.

4. Each Insufficient Documentation Claim identified on **Schedule 2** hereto is disallowed and expunged in its entirety.

5. Each Amended and Superseded Claim identified on **Schedule 3** hereto is disallowed and expunged in its entirety. Each Remaining Claim listed under the column labeled "Remaining Claim" on **Schedule 3** hereto shall remain on the Claims Register, subject to the rights of any party in interest to object to such claims on any and all grounds.

6. The objection by the Debtor to the Disputed Claims, as addressed in the Objection and the schedules hereto, constitutes a separate contested matter with respect to each such Proof of Claim, as contemplated by Bankruptcy Rule 9014 and Local Rule 3007-1. This Order shall be deemed a separate Order with respect to each Disputed Claim.

7. Any stay of this Order pending appeal by any holder of a Disputed Claim or any other party with an interest in such claims that are subject to this Order shall only apply to the contested matter which involves such party and shall not act to stay the applicability and/or finality of this Order with respect to the other contested matters arising from the Objection or this Order.

8. The rights of the Debtor, or any other party in interest, as applicable, to (a) file subsequent objections to any Disputed Claims on any ground, (b) amend, modify, and/or supplement the Objection, including, without limitation, the filing of objections to further amended or newly filed claims, (c) seek expungement or reduction of any claim to the extent all or a portion of such claim has been paid, and (d) settle any claim for less than the asserted amount are preserved.

9. The Debtor and Verita are authorized to modify the Claims Register to comport with the entry of this Order.

10. The Debtor is authorized to take all reasonable actions necessary or appropriate to implement and effectuate the relief granted in this Order.

11. The Court shall retain jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and/or enforcement of this Order.

Schedule 1

Equity Interest Claims

SGMO - Schedule 1 - Equity Interest Claims

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
1	Blake, Barbara Kate	08/08/2026	34	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 286.40	
					Total	**$ 286.40**	
2	Blake, Barbara Kate	08/14/2026	51	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 284.16	
					Total	**$ 284.16**	
3	Burke, Mark	08/08/2026	36	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 4,666.00	
					Total	**$ 4,666.00**	
4	Chapman, Claire	08/24/2026	78	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 652.96	
					Total	**$ 652.96**	
5	Ciprian, Peter K	06/29/2026	1	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	$ 400,000.00	
					Total	**$ 400,000.00**	
6	Ciprian, Peter K	08/17/2026	56	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ 50,000.00	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 50,000.00**	
7	Dai, Bich	09/17/2026	316	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ 10.78	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 10.78**	
8	Dashinsky, Jason	08/19/2026	67	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 596.25	
					Total	**$ 596.25**	
9	Deegan, F. Timothy	09/01/2026	128	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 6,820.00	
					Total	**$ 6,820.00**	
10	Deegan, F. Timothy	09/01/2026	130	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	$ 6,164.22	
					Total	**$ 6,164.22**	
11	DelaCruz, Neslihan	09/10/2026	180	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 1,734.73	
					Total	**$ 1,734.73**	
12	Flammang, Beverly A	09/11/2026	207	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 22,058.00	
					Total	**$ 22,058.00**	
13	Gao, Yuan	09/09/2026	160	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 14,800.00	
					Total	**$ 14,800.00**	
14	Garber, Tomer	09/08/2026	154	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 10,000.00	
					Total	**$ 10,000.00**	
15	Gellhaus, Katharina	09/29/2026	438	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	UNLIQUIDATED	
					Total	**Unliquidated**	
16	Haley, James D.	07/21/2026	22	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 10,250.65	
					Total	**$ 10,250.65**	
17	Herbst, Kathy Helen	08/14/2026	50	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 2,754.98	
					Total	**$ 2,754.98**	
18	Hester, Diem	09/15/2026	270	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 591.00	
					Total	**$ 591.00**	
19	Hester, Diem L	09/15/2026	268	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 1,505.00	
					Total	**$ 1,505.00**	
20	Kalessa, Joann	08/18/2026	59	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	$ 5,649.05	
					Total	**$ 5,649.05**	
21	Kapur, Tripat Pal Singh	08/20/2026	72	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 709.14	
					Total	**$ 709.14**	
22	Krause, Martin	09/29/2026	437	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 5,152.00	
					Total	**$ 5,152.00**	
23	Lai, Li H	08/20/2026	73	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 5,695.88	
					Total	**$ 5,695.88**	
24	Lewak, Myrna	09/22/2026	423	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 45,000.00	
					Total	**$ 45,000.00**	
25	Mahmoud, Hisham	08/21/2026	75	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	CAD 971.50	
					Total	**CAD 971.50**	
26	Nalpant, Edward A	08/08/2026	35	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ 14,880.51	
					Unsecured	$ -	
					Total	**$ 14,880.51**	
27	Neyhart, Dirk	09/15/2026	260	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 1,272.44	
					Total	**$ 1,272.44**	
28	Overley, Rose Ann	08/27/2026	97	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ 4,675.36	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 4,675.36**	
29	Paszewski, Carol	08/06/2026	28	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 1,309.00	
					Total	**$ 1,309.00**	
30	Powers, Robert E	08/12/2026	48	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	UNLIQUIDATED	
					Total	**Unliquidated**	
31	Ramelmeier, Rolf	09/24/2026	436	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ 3,833.43	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 3,833.43**	
32	Riordan, Rebecca	09/22/2026	419	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 100,000.00	
					Total	**$ 100,000.00**	
33	Rivera, Alex	08/18/2026	62	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 7,549.99	
					Total	**$ 7,549.99**	
34	Sanclemente, Daniel A	08/12/2026	42	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 444.08	
					Total	**$ 444.08**	
35	Thurgarland, Barbara	09/22/2026	406	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	

Claims Filed on Account of Equity Interests							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
					Priority	$ -	
					Unsecured	$ 14,104.14	
					Total	**$ 14,104.14**	
36	Withers, Matthew	09/22/2026	415	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ -**	
37	Wong, Anne	09/07/2026	150	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 1,277.37	
					Total	**$ 1,277.37**	
38	Wortman, Stephen A.	09/02/2026	137	Sangamo Therapeutics, Inc.	Admin	$ -	This claim was filed on account of ownership of an equity interest and is not a claim under the Bankruptcy Code.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ 189.42	
					Unsecured	$ -	
					Total	**$ 189.42**	

Schedule 2

Insufficient Documentation Claims

SGMO - Schedule 2 - Insufficient Documentation Claims

Insufficient Documentation Claims							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
1	2170678 Ontario Inc	08/26/2026	91	Sangamo Therapeutics, Inc.	Admin 503(b)(9) Secured Priority Unsecured **Total**	$ - $ - $ - $ - $ 7,500.00 **$ 7,500.00**	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
2	Amuza, Inc.	08/25/2026	82	Sangamo Therapeutics, Inc.	Admin 503(b)(9) Secured Priority Unsecured **Total**	$ - $ - $ - $ - $ - **$ -**	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
3	Antoniuk, Oleksandr	08/21/2026	76	Sangamo Therapeutics, Inc.	Admin 503(b)(9) Secured Priority Unsecured **Total**	$ - $ - $ - $ - $ - **$ -**	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
4	Austin, Jillian	09/22/2026	431	Sangamo Therapeutics, Inc.	Admin 503(b)(9) Secured Priority Unsecured **Total**	$ - $ - $ - $ - $ - **$ -**	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
5	Elayaperumal, Piramiah	08/21/2026	74	Sangamo	Admin	$ -	This claim does not include sufficient

Insufficient Documentation Claims							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
				Therapeutics, Inc.	503(b)(9)	$ 2,309.00	documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 2,309.00**	
6	Fubon Insurance Co., Ltd.	08/31/2026	132	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ -**	
7	Kolesnikov, Sergei	08/09/2026	37	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 46,809.42	
					Total	**$ 46,809.42**	
8	Matuk, Helen	08/29/2026	116	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 200.00	
					Total	**$ 200.00**	
9	Pokorney, Bob	08/24/2026	81	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ 873.74	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ 873.74**	

Insufficient Documentation Claims							
No.	**Claimant Name**	**Claim to be Disallowed**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	
10	San Francisco Lessee, Inc.	08/17/2026	55	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ -	
					Total	**$ -**	
11	Singh, Kulwinder	08/26/2026	89	Sangamo Therapeutics, Inc.	Admin	$ -	This claim does not include sufficient documentation to constitute prima facie evidence of the validity and amount of the claim, and the Debtors' books and records do not reflect any basis for the claim on behalf of this claimant.
					503(b)(9)	$ -	
					Secured	$ -	
					Priority	$ -	
					Unsecured	$ 35,000.00	
					Total	**$ 35,000.00**	

Schedule 3

Amended and Superseded Claims

SGMO - Schedule 3 - Amended and Superseded Claims

Amended & Superseded Claims												
No.	**Claimant Name**	**Amended Claim to be Disallowed**					**Remaining Claim**					**Reason**
		Date Filed	**Claim #**	**Debtor**	**Priority**	**Amount**	**Date Filed**	**Claim #**	**Debtor**	**Priority**	**Amount**	
1	Aerotek Inc	08/17/2026	57	Sangamo Therapeutics, Inc.	Admin	$ -	09/04/2026	143	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 57 was amended and superseded by Claim No. 143
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 38,297.76				Unsecured	$ 38,744.52	
					Total	**$ 38,297.76**				**Total**	**$ 38,744.52**	
2	Almac Clinical Services LLC	07/22/2026	20	Sangamo Therapeutics, Inc.	Admin	$ -	08/07/2026	32	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 20 was amended and superseded by Claim No. 32
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 10,204.19				Unsecured	$ 10,057.68	
					Total	**$ 10,204.19**				**Total**	**$ 10,057.68**	
3	Brammer Bio MA, LLC	09/01/2026	129	Sangamo Therapeutics, Inc.	Admin	$ -	09/22/2026	412	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 129 was amended and superseded by Claim No. 412
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 10,903,579.36				Unsecured	$ 10,903,579.36	
					Total	**$ 10,903,579.36**				**Total**	**$ 10,903,579.36**	
4	Connor Group Global Services, LLC	08/11/2026	39	Sangamo Therapeutics, Inc.	Admin	$ -	09/08/2026	152	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 39 was amended and superseded by Claim No. 152
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 48,766.25				Unsecured	$ 61,886.25	
					Total	**$ 48,766.25**				**Total**	**$ 61,886.25**	
5	CRG Financial LLC	07/20/2026	17	Sangamo Therapeutics, Inc.	Admin	$ -	09/22/2026	417	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 17 was amended and superseded by Claim No. 417
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 67,317.25				Unsecured	$ 67,317.25	
					Total	**$ 67,317.25**				**Total**	**$ 67,317.25**	
6	Fisher Bioservices, Inc.	09/18/2026	318	Sangamo Therapeutics, Inc.	Admin	$ -	09/22/2026	411	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 318 was amended and superseded by Claim No. 411
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 210,413.63				Unsecured	$ 210,413.63	
					Total	**$ 210,413.63**				**Total**	**$ 210,413.63**	

Amended & Superseded Claims												
No.	Claimant Name	Amended Claim to be Disallowed					Remaining Claim					Reason
		Date Filed	Claim #	Debtor	Priority	Amount	Date Filed	Claim #	Debtor	Priority	Amount	
7	PPD Development, L.P.	09/17/2026	294	Sangamo Therapeutics, Inc.	Admin	$ -	09/22/2026	416	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 294 was amended and superseded by Claim No. 416
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 1,416,064.57				Unsecured	$ 1,416,064.57	
					Total	**$ 1,416,064.57**				**Total**	**$ 1,416,064.57**	
8	San Mateo County Tax Collector	08/24/2026	79	Sangamo Therapeutics, Inc.	Admin	$ -	09/03/2026	139	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 79 was amended and superseded by Claim No. 139
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ 118,868.35				Priority	$ -	
					Unsecured	$ -				Unsecured	$ -	
					Total	**$ 118,868.35**				**Total**	**$ -**	
9	VEOLIA ES TECHNICAL SOLUTIONS, L.L.C.	07/02/2026	5	Sangamo Therapeutics, Inc.	Admin	$ -	08/26/2026	93	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 5 was amended and superseded by Claim No. 93
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 86,404.61				Unsecured	$ 118,175.37	
					Total	**$ 86,404.61**				**Total**	**$ 118,175.37**	
10	VEOLIA ES TECHNICAL SOLUTIONS, L.L.C.	08/26/2026	93	Sangamo Therapeutics, Inc.	Admin	$ -	08/26/2026	94	Sangamo Therapeutics, Inc.	Admin	$ -	Claim No. 93 was amended and superseded by Claim No. 94
					503(b)(9)	$ -				503(b)(9)	$ -	
					Secured	$ -				Secured	$ -	
					Priority	$ -				Priority	$ -	
					Unsecured	$ 118,175.37				Unsecured	$ 118,175.37	
					Total	**$ 118,175.37**				**Total**	**$ 118,175.37**	

EXHIBIT B

Li Declaration

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	

DECLARATION OF RAYMOND LI IN SUPPORT OF DEBTOR'S FIRST OMNIBUS OBJECTION (NON-SUBSTANTIVE) TO CERTAIN (I) CLAIMS FILED ON ACCOUNT OF EQUITY INTERESTS, (II) INSUFFICIENT DOCUMENTATION CLAIMS AND (III) AMENDED AND SUPERSEDED CLAIMS

I, Raymond Li, hereby declare under penalty of perjury that the following is true and correct to the best of my knowledge, information, and belief:

1. I am a Managing Director of MERU, LLC ("**MERU**"), a professional services firm, with numerous offices throughout the country. On July 30, 2026, the Court entered an order authorizing the Debtor to employ MERU as its financial advisor in connection with the Chapter 11 Case. *See* Docket No. 201. Unless otherwise stated in this declaration (this "**Declaration**"), I have personal knowledge of the facts set forth herein and, if called as a witness, I could and would testify thereto.

2. I submit this Declaration in support of the *Debtor's First Omnibus Objection (Non-Substantive) to Certain (I) Claims Filed on Account of Equity Interests, (II) Insufficient Documentation Claims, and (III) Amended and Superseded Claims* (the "**Objection**").[2]

3. I am over the age of 18 years and authorized to submit this Declaration on behalf of the Debtor. I am not being specifically compensated for this testimony.

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 470 Noor Ave., Suite B #1306, South San Francisco, CA 94080.

[2] Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Objection.

a. Equity Interest Claims

4. Based upon review and analysis of the Equity Interest Claims listed on **Schedule 1** to the Proposed Order, my team and I have determined that each Equity Interest Claim listed on **Schedule 1** to the Proposed Order was filed by a shareholder based on the asserted ownership of equity securities in the Debtor. The Equity Interest Claims do not assert any claims for damages, but rather assert claims based only on ownership of equity interests. My team and I were able to identify the claimants that asserted the Equity Interest Claims because almost all of those claimants noted on their Proof of Claim form that their claim was filed on account of such an interest and/or such claimants filed documentation evidencing their equity interest with their Proof of Claim form.

5. The elimination of the Equity Interest Claims will enable the Debtor to maintain a Claims Register that more accurately reflects the claims that have been asserted by the Debtor's creditors. As such, I believe the disallowance and expungement of the Equity Interest Claims on the terms set forth in the Objection is appropriate.

b. Insufficient Documentation Claims

6. Based upon a careful review and analysis of the Debtor's Books and Records, the Debtor's Schedules and Statement, and the Insufficient Documentation Claims (including the related supporting documentation or lack thereof attached thereto), my team and I have determined that (i) the Insufficient Documentation Claims listed on **Schedule 2** to the Proposed Order provide insufficient substantiation for the asserted claims and (ii) the Debtor's Books and Records do not reflect the existence of, or factual support for, the Insufficient Documentation Claims.

7. The Insufficient Documentation Claims were carefully reviewed by the appropriate personnel of the Debtor and its professionals. Based on that review, the Insufficient Documentation Claims do not (i) contain any supporting documentation or (ii) provide any specificity as to what facts support the asserted claims. Additionally, after a reasonable investigation, no information

was found in the Debtor's Books and Records evidencing an outstanding obligation or liability owed to the relevant claimant by the Debtor on any basis.

8. Based on the foregoing, I believe there is no valid legal justification for the Insufficient Documentation Claims. I further believe that failure to disallow and expunge the Insufficient Documentation Claims would result in claims that have been improperly asserted against the Debtor and its estate remaining on the Claims Register and in certain creditors receiving improper recoveries on account of such claims to the detriment of the Debtor's other stakeholders. Moreover, I believe that disallowing and expunging the Insufficient Documentation Claims, as set forth on **Schedule 2** attached to the Proposed Order, will enable the Debtor to maintain a more accurate Claims Register. As such, I believe the disallowance and expungement of the Insufficient Documentation Claims on the terms set forth in the Objection is appropriate.

c. Amended and Superseded Claims

9. Based upon my review and analysis of the Amended and Superseded Claims listed on **Schedule 3** to the Proposed Order, each Amended and Superseded Claim listed under the column "Amended Claim to be Disallowed" has been amended and superseded by a subsequently filed proof of claim by the same claimant and on account of the same liability as those listed under the column labeled "Remaining Claim." Indeed, each such Remaining Claim indicates that it amends a prior claim and most of the Remaining Claims identify the Amended and Superseded Claim that they amend.

10. Accordingly, after careful review, it is my belief that all of the Amended and Superseded Claims listed under the column "Amended Claim to be Disallowed" have in fact been amended and superseded by the corresponding Remaining Claims. The elimination of the Amended and Superseded Claims will enable the Debtor to maintain a Claims Register that more accurately reflects the claims that have been asserted against the Debtor's estate and to avoid

paying twice on the same obligation. As such, I believe the disallowance and expungement of the Amended and Superseded Claims on the terms set forth in the Objection is appropriate.

11. I declare under penalty of perjury that the foregoing is true and correct.

Dated: November 13, 2026

/s/ Raymond Li
Name: Raymond Li
Title: Managing Director